On September 3, 2025 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for cancer, reported it will host two virtual investor and analyst events to spotlight its innovative farnesyl transferase inhibitor (FTI) program (Press release, Kura Oncology, SEP 3, 2025, View Source [SID1234655729]). These events will underscore Kura’s leadership in targeting cancer signaling pathways to address unmet needs in solid tumors and hematologic malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event Details:

FTI Preclinical Program Review: Synergistic Combinations with Targeted Therapies
Tuesday, September 16, 2025
1:30 p.m. PT / 4:30 p.m. ET
This event will explore the scientific foundation, mechanisms of action and preclinical data supporting the combination of FTIs with tyrosine kinase inhibitors (TKIs), RAS inhibitors, and PI3K alpha inhibitors, highlighting their potential to transform treatment for solid tumors.

Discussion of Clinical Data Presented at 2025 ESMO (Free ESMO Whitepaper) Congress, Including First Clinical Data from KO-2806, Kura’s Next-Generation FTI
Saturday, October 18, 2025
10:30 a.m. PT / 1:30 p.m. ET
This event will dive into clinical data presented at the 2025 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, including the first clinical insights from KO-2806, Kura’s next-generation FTI, showcasing its potential to address resistance mechanisms in cancer.
Live audio webcasts will be available in the Investors section of Kura’s website at View Source, with archived replays available following both events.

Details of the presentations at ESMO (Free ESMO Whitepaper) Congress 2025 are as follows:

Farnesyltransferase inhibitor (FTI) KO-2806 in combination with cabozantinib (cabo) in renal cell carcinoma (RCC): Preliminary results from FIT-001 phase 1 trial
Saturday, October 18, 2025; 12:00 PM CEST
Publication Number 2604P

A phase 1 study of the next-generation farnesyltransferase inhibitor (FTI) KO-2806 as monotherapy in advanced solid tumors
Sunday, October 19, 2025; 12:00 PM CEST
Publication Number 981P

Tipifarnib (TIP) and alpelisib (ALP) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 1 results from KURRENT-HN
Monday, October 20, 2025; 12:00 PM CEST
Publication Number 1349P

The three posters presented at ESMO (Free ESMO Whitepaper) Congress 2025 will be available to view in the "Pipeline/Posters and Presentations" section on Kura’s website at approximately 12:05 a.m. PT / 3:05 a.m. ET on October 18, 2025.